109 related articles for article (PubMed ID: 29274785)
1. Indirubin 3'-oxime inhibits anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells.
Tanaka T; Ohashi S; Saito H; Wada T; Aoyama T; Ichimaru Y; Miyairi S; Kobayashi S
Biochem Biophys Res Commun; 2018 Jan; 496(1):7-11. PubMed ID: 29274785
[TBL] [Abstract][Full Text] [Related]
2. Mechanism responsible for inhibitory effect of indirubin 3'-oxime on anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells.
Tanaka T; Kasai M; Kobayashi S
Exp Cell Res; 2018 Sep; 370(2):454-460. PubMed ID: 29981748
[TBL] [Abstract][Full Text] [Related]
3. 7-Hydorxyindirubin is capable of specifically inhibiting anticancer drug-induced YB-1 nuclear translocation without showing cytotoxicity in HepG2 hepatocellular carcinoma cells.
Tanaka T; Saito H; Miyairi S; Kobayashi S
Biochem Biophys Res Commun; 2021 Mar; 544():15-21. PubMed ID: 33516877
[TBL] [Abstract][Full Text] [Related]
4. Four nucleocytoplasmic-shuttling proteins and p53 interact specifically with the YB-NLS and are involved in anticancer reagent-induced nuclear localization of YB-1.
Tanaka T; Ohashi S; Kobayashi S
Biochem Biophys Res Commun; 2016 Sep; 478(3):1363-9. PubMed ID: 27565728
[TBL] [Abstract][Full Text] [Related]
5. [Effects of changwelqing on nuclear translocation of Y-box binding protein-1 and expression of P-glycoprotein in human colon cancer cell line with drug-resistance induced by vincristine].
Xu JH; Deng WL; Fan ZZ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Jul; 30(7):743-7. PubMed ID: 20929136
[TBL] [Abstract][Full Text] [Related]
6. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
7. Indirubin 3'-(O-oxiran-2-ylmethyl)oxime: a novel anticancer agent.
Ichimaru Y; Saito H; Uchiyama T; Metori K; Tabata K; Suzuki T; Miyairi S
Bioorg Med Chem Lett; 2015 Apr; 25(7):1403-6. PubMed ID: 25765906
[TBL] [Abstract][Full Text] [Related]
8. Indirubin derivatives alter DNA binding activity of the transcription factor NF-Y and inhibit MDR1 gene promoter.
Tanaka T; Ohashi S; Saito H; Higuchi T; Tabata K; Kosuge Y; Suzuki T; Miyairi S; Kobayashi S
Eur J Pharmacol; 2014 Oct; 741():83-9. PubMed ID: 25066113
[TBL] [Abstract][Full Text] [Related]
9. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.
Tiwari A; Rebholz S; Maier E; Dehghan Harati M; Zips D; Sers C; Rodemann HP; Toulany M
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126195
[TBL] [Abstract][Full Text] [Related]
10. Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells.
Kameswaran TR; Ramanibai R
Biomed Pharmacother; 2009 Feb; 63(2):146-54. PubMed ID: 18450412
[TBL] [Abstract][Full Text] [Related]
11. 5-diphenylacetamido-indirubin-3'-oxime as a novel mitochondria-targeting agent with anti-leukemic activities.
Song JH; Lee JE; Cho KM; Park SH; Kim HJ; Kim YC; Kim TS
Mol Carcinog; 2016 May; 55(5):611-21. PubMed ID: 25788004
[TBL] [Abstract][Full Text] [Related]
12. Transportin-1-dependent YB-1 nuclear import.
Mordovkina DA; Kim ER; Buldakov IA; Sorokin AV; Eliseeva IA; Lyabin DN; Ovchinnikov LP
Biochem Biophys Res Commun; 2016 Nov; 480(4):629-634. PubMed ID: 27794479
[TBL] [Abstract][Full Text] [Related]
13. 5-Bromoindirubin 3'-(O-oxiran-2-ylmethyl)oxime: A long-acting anticancer agent and a suicide inhibitor for epoxide hydrolase.
Ichimaru Y; Fujii T; Saito H; Sano M; Uchiyama T; Miyairi S
Bioorg Med Chem; 2017 Sep; 25(17):4665-4676. PubMed ID: 28743492
[TBL] [Abstract][Full Text] [Related]
14. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
Yamashita T; Higashi M; Momose S; Morozumi M; Tamaru JI
Int J Oncol; 2017 Aug; 51(2):579-586. PubMed ID: 28714514
[TBL] [Abstract][Full Text] [Related]
15. Indirubin-3'-oxime impairs mitochondrial oxidative phosphorylation and prevents mitochondrial permeability transition induction.
Varela AT; Gomes AP; Simões AM; Teodoro JS; Duarte FV; Rolo AP; Palmeira CM
Toxicol Appl Pharmacol; 2008 Dec; 233(2):179-85. PubMed ID: 18786556
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
18. 5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.
Ahn MY; Kim TH; Kwon SM; Yoon HE; Kim HS; Kim JI; Kim YC; Kang KW; Ahn SG; Yoon JH
Eur J Pharm Sci; 2015 Nov; 79():122-31. PubMed ID: 26342773
[TBL] [Abstract][Full Text] [Related]
19. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
20. [Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
Rybalkina EIu; Stromskaia TP; Ovchinnikov LP; Stavrovskaia AA
Vopr Onkol; 2013; 59(5):623-8. PubMed ID: 24260892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
